ACR-2316
ACR-2316-101
Phase 1 small_molecule active
Quick answer
ACR-2316 for Specific Advanced Solid Tumors is a Phase 1 program (small_molecule) at Acrivon Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Acrivon Therapeutics
- Indication
- Specific Advanced Solid Tumors
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active